AdultPediatricDosage Forms & Strengths tablet 1mg 2mg 4mg 6mg 8mg 10mg 12mg Schizophrenia Day 1: 1 mg PO q12hr; increase qDay to effective dose of 6-12 mg PO q12hr Day 2: 2 mg PO q12hr, THEN increase qDay by 2 mg/day to effective dose of 6-12 mg PO q12hr; not to exceed 24 mg/day Must gradually increase dose to avoid orthostatic hypotension Dosing considerations In a longer-term study, this drug was effective in delaying time to relapse in patients with schizophrenia who were stabilized on this drug up to 24 mg/day; patients should be periodically reassessed to determine need for maintenance treatment Although there are no data to specifically address reinitiation of treatment, it is recommended that initiation titration schedule be followed whenever patients have had an interval off therapy of more than 3 days When deciding among alternative treatments available, the prescriber should consider the finding that this drug is associated with prolongation of QTc interval Prolongation of QTc interval is associated in some other drugs with ability to cause torsade de pointes type arrhythmia, a potentially fatal polymorphic ventricular tachycardia which can result in sudden death In many cases this would lead to conclusion that other drugs should be tried first; whether this drug will cause torsade de pointes or increase rate of sudden death is not yet known Patients must be titrated to an effective dose; thus, control of symptoms may be delayed during first 1 to 2 weeks of treatment compared to some other antipsychotic drugs that do not require a similar titration Prescribers should be mindful of this delay when selecting an antipsychotic drug for treatment of schizophrenia Dosage Modifications Coadministration with strong CYP2D6 or CYP3A4 inhibitors: Decrease iloperidone dose by 50% Poor CYP2D6 metabolizers: Decrease iloperidone dose by 50% Renal impairment: Unlikely to have a significant impact since <1% of drug is excreted unchanged in urine Hepatic impairment Mild: No dosage adjustment required Moderate: Caution advised Severe: Use not recommended Safety and efficacy not establishedInteraction CheckerEnter a drug name and iloperidoneNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (5)amisulprideamisulpride, iloperidone. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndromeIncreases risk of neuroleptic malignant syndrome.flibanseriniloperidone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of flibanserin with moderate or strong CYP3A4 inhibitors is contraindicated. Severe hypotension or syncope can occur.goserelingoserelin increases toxicity of iloperidone by QTc interval. Contraindicated. Increases risk of torsades de pointes.leuprolideleuprolide increases toxicity of iloperidone by QTc interval. Contraindicated. Increases risk of torsades de pointes.lonafarnibiloperidone will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is a sensitive CYP3A4 substrate. Coadministration with strong or moderate CYP3A4 inhibitors is contraindicated. Serious - Use Alternative (135)adagrasibadagrasib, iloperidone. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.alfuzosinalfuzosin and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.amiodaroneamiodarone and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.amisulprideamisulpride and iloperidone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.anagrelideanagrelide and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.apomorphineiloperidone decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.apomorphine and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.aripiprazolearipiprazole and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.arsenic trioxidearsenic trioxide and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.artemetherartemether and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.artemether/lumefantrineartemether/lumefantrine will increase the level or effect of iloperidone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.asenapineasenapine and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.asenapine transdermalasenapine transdermal and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.atomoxetineatomoxetine and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.avapritinibiloperidone will increase the level or effect of avapritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of avapritinib with moderate CYP3A4 inhibitors. If unable to avoid, reduce avapritinib starting dose. See drug monograph Dosage Modifications.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen, iloperidone. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.bromocriptineiloperidone decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.buprenorphinebuprenorphine and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine buccalbuprenorphine buccal and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine subdermal implantbuprenorphine subdermal implant and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine transdermalbuprenorphine transdermal and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine, long-acting injectionbuprenorphine, long-acting injection and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.cabergolineiloperidone decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated.calcium/magnesium/potassium/sodium oxybatesiloperidone, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.carbamazepinecarbamazepine will decrease the level or effect of iloperidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.ceritinibceritinib and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.cimetidinecimetidine will increase the level or effect of iloperidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.clozapineclozapine and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.cobimetinibiloperidone will increase the level or effect of cobimetinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If concurrent short term (14 days or less) use of moderate CYP3A inhibitors is unavoidable for patients who are taking cobimetinib 60 mg, reduce the cobimetinib dose to 20 mg. After discontinuation of a moderate CYP3A inhibitor, resume cobimetinib 60 mg. Use an alternative to a moderate CYP3A inhibitor in patients who are taking a reduced dose of cobimetinib (40 or 20 mg daily).dacomitinibdacomitinib will increase the level or effect of iloperidone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid use with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities. degarelixdegarelix and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.desfluranedesflurane and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.disopyramidedisopyramide and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.donepezildonepezil and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.dopamineiloperidone decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.efavirenzefavirenz and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.elacestrantiloperidone will increase the level or effect of elacestrant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.eliglustatiloperidone increases levels of eliglustat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Moderate CYP3A4 inhibitors are not recommended with eliglustat poor or intermediate metabolizers; reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive metabolizers .eliglustat and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.encorafenibiloperidone will increase the level or effect of encorafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If concomitant use of a moderate CYP3A4 inhibitor is unavoidable, reduce encorafenib dose to one-half of the dose (eg, reduce from 450 mg/day to 225 mg/day). After discontinuing the inhibitor for 3-5 elimination half-lives, resume previous encorafenib dose.encorafenib and iloperidone both increase QTc interval. Avoid or Use Alternate Drug. Encorafenib is associated with dose-dependent QTc interval prolongation. Avoid with drugs known to prolong QT interval.entrectinibiloperidone and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.iloperidone will increase the level or effect of entrectinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of moderate CYP3A4 inhibitors with entrectinib, a CYP3A4 substrate. If coadministration unavoidable, reduce dose to 200 mg/day for patients aged 12 y or older with BSA >1.50m2. Resume previous entrectinib dose after discontinuing moderate CYP3A inhibitor for 3-5 elimination half-lives.eribulineribulin and iloperidone both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.erythromycin baseerythromycin base will increase the level or effect of iloperidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.erythromycin ethylsuccinateerythromycin ethylsuccinate will increase the level or effect of iloperidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.erythromycin lactobionateerythromycin lactobionate will increase the level or effect of iloperidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.erythromycin stearateerythromycin stearate will increase the level or effect of iloperidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.escitalopramescitalopram increases toxicity of iloperidone by QTc interval. Avoid or Use Alternate Drug.fentanyliloperidone will increase the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4 inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.fentanyl intranasaliloperidone will increase the level or effect of fentanyl intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4 inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.fentanyl transdermaliloperidone will increase the level or effect of fentanyl transdermal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4 inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.fentanyl transmucosaliloperidone will increase the level or effect of fentanyl transmucosal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4 inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.fexinidazolefexinidazole and iloperidone both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval.fingolimodfingolimod and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.fluoxetinefluoxetine will increase the level or effect of iloperidone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.gemifloxacingemifloxacin and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.gilteritinibgilteritinib and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.givosirangivosiran will increase the level or effect of iloperidone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP2D6 substrates with givosiran. If unavoidable, decrease the CYP2D6 substrate dosage in accordance with approved product labeling.glasdegibiloperidone and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.granisetrongranisetron and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.histrelinhistrelin increases toxicity of iloperidone by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.hydrocodonehydrocodone, iloperidone. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.hydroxychloroquine sulfatehydroxychloroquine sulfate and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.hydroxyzinehydroxyzine increases toxicity of iloperidone by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.ibutilideibutilide and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.indapamideiloperidone and indapamide both increase QTc interval. Avoid or Use Alternate Drug.infigratinibiloperidone will increase the level or effect of infigratinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.inotuzumabinotuzumab and iloperidone both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes